Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth

An antisense oligonucleotide, oligonucleotide technology, applied in the field of pharmaceutical compositions, can solve problems such as permanent vision loss

Inactive Publication Date: 2001-06-06
GENESENSE TECHNOLOGIES INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The resulting hypoxia triggers subsequent retinal neovascularization leading to permanent vision loss

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
  • Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
  • Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0144] Prepare hard gelatin capsules containing the following ingredients: Element Dosage (mg / capsule) Active ingredient 30.0 Starch 305.0 Magnesium stearate 5.0

[0145] The above ingredients are mixed and filled into hard gelatin capsules in an amount of 340 mg per capsule.

preparation Embodiment 2

[0147] A tablet formulation was prepared using the following ingredients: Element Dosage (mg / tablet) Active Ingredient 25.0 Microcrystalline Cellulose 200.0 Colloidal Silicon Dioxide 10.0 Stearic Acid 5.0

[0148] The ingredients listed above are blended and compressed into tablets, each weighing 240 mg.

preparation Embodiment 3

[0150] A dry powder inhalation formulation is prepared comprising the following ingredients: Element weight percentage (%) Active ingredient 5 lactose 95

[0151] The active ingredient and lactose are mixed and the mixture is filled into a powder inhaler.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an oligonucleotide complementary to neurofibrillin gene, which can regulate tumor cell growth and angiogenesis in mammals. The invention also relates to methods of using such compounds in the inhibition of tumor cell growth and angiogenesis in mammals. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of the compound of the present invention.

Description

[0001] References to related applications [0002] This application claims priority from US Provisional Application Serial No. 60 / 082,791 (filed April 23, 1988), which is incorporated herein by reference in its entirety. Background of the invention [0003] field of invention [0004] The present invention relates to oligonucleotides complementary to mammalian neuroflammulin (or VEGF165R) mRNA, which can regulate cell growth in mammals. The invention also relates to methods of using such compounds in inhibiting the growth of tumor cells in mammals and inhibiting angiogenesis in mammals. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of a compound of the present invention. [0005] references [0006] The following publications, patent applications and patents are referenced by number in this application: [0007] 1. Tischer, E., et al.,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K31/711A61K38/00A61K45/06A61K48/00A61P35/00A61P35/04C12N15/113
CPCC12N15/1136A61K38/00C12N2310/315C12N2310/111A61P35/00A61P35/04C12N15/11
Inventor J·A·赖特A·H·扬Y·S·李
Owner GENESENSE TECHNOLOGIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com